This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Isis Pharmaceuticals To Provide Update On Its Metabolic Franchise

CARLSBAD, Calif., Dec. 3, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will highlight three drugs from Isis' metabolic franchise in a conference call and webcast on Friday, December 7, 2012 at 12:00 p.m. Eastern Time.  This call will be archived for a limited time on Isis' Web site.

In this call, Isis will highlight three drugs, ISIS-PTP1B Rx, ISIS-GCGR Rx and ISIS-GCCR Rx, from its metabolic franchise, and discuss the potential therapeutic context for each drug in the treatment paradigm for patients with type 2 diabetes.

CONFERENCE CALL At 12:00 p.m. Eastern Time, Friday, December 7, 2012, Isis will conduct a live webcast and conference call.  Interested parties may listen to the call by dialing 1-866-362-4831, or 1-617-597-5347 for international callers, and refer to passcode "ISIS 2012."  The webcast can be accessed at wwww.isispharm.com.  A webcast replay will be available for a limited time at the same address. 



ISIS' METABOLIC FRANCHISEIsis is pursuing the discovery and development of antisense drugs to treat metabolic diseases, such as diabetes.  According to the Centers for Disease Control and Prevention, diabetes affects more than 25 million people in the U.S.  Isis has three drugs in its pipeline to treat type 2 diabetes, each of which acts upon targets in the liver or fat tissue through distinct mechanisms to improve insulin sensitivity, reduce glucose production, or affect other aspects of metabolic disease.  Isis is developing other drugs aimed at other types of metabolic diseases.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS' FORWARD-LOOKING STATEMENT   This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of the drugs in Isis' metabolic pipeline. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs